Egypt’s $400M Generic Pharma Hub Targets Import Dependence
A $400M pharmaceutical complex east of Cairo aims to reduce MENA dependence on imported generics by 35% within five years.
Construction has begun on a $400 million generic-drug manufacturing complex in Egypt’s 10th of Ramadan industrial zone. Planned output covers 180 molecules across cardiology, oncology, and anti-infective therapy classes.
The project is a public-private partnership between the Egyptian state and a consortium of Saudi and Emirati pharmaceutical investors. Commercial output is scheduled for Q4 2027.
